O'Donnell 1993

Methods	Country: UK Setting/Design: University Time frame: NS Randomisation method: NS Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: No Follow‐up period: 48 weeks Loss to follow‐up: 9
Participants	Inclusion criteria DM: Type 1 or 2 Age: 18‐70 years Incipient diabetic nephropathy DBP: Resting ≤ 90 mm Hg Lisinopril group Number: 15 Age: 48.3 (13.0) Sex (M/F): 11/4 Placebo group Number: 17 Age: 49.1 (16.0) Sex (M/F): 12/5 Exclusion criteria Hypertension of any aetiology Heart failure, aortic outflow obstruction, unstable angina or MI in the preceding 3 months Renal disease other than diabetic nephropathy SCr > 140 µmol/L Low protein diet Systemic malignancy Clinically significant abnormality of hepatic, haemopoietic or endocrine function Women of childbearing potential not using a medically acceptable method of birth control Continuous subcutaneous insulin infusion Hypersensitivity to ACEi Treatment with the following medications: aldose reductase inhibitors, myoinositol, steroids, gold, penicillamine, NSAIDs, monoamine oxidase inhibitors, appetite suppressants, lithium, vasopressor nasal decongestants or cimetidine
Interventions	Lisinopril group 10 mg/d Placebo group Co‐interventions: No
Outcomes	AER Urinary excretion of prostaglandins GFR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear